Venus Remedies gets marketing authorisation for anticoagulant ‘Enoxaparin’ from Indonesia
Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations
Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian exporter of generic drugs, has received marketing authorisation from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in pre-filled syringes across all major strengths. This approval reinforces the company’s presence in Indonesia and aligns with its broader expansion strategy in Southeast Asia.
“Indonesia has the highest burden of cardiovascular diseases in the region, driven by an aging population and lifestyle changes. Our Enoxaparin will offer a cost-effective solution to manage clot-related conditions,” said Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre.
Enoxaparin, a key anticoagulant, helps prevent and treat blood clots, reducing the risk of deep vein thrombosis and pulmonary embolism. The global Enoxaparin market, valued at USD 3.3 billion in 2023, is projected to reach USD 5.4 billion by 2032, growing at a CAGR of 7.1%–7.9%. Venus Remedies, with an annual production capacity exceeding 10 million units at its autonomous robotic facility, is well-positioned to capture a significant market share in Southeast Asia and beyond.
The Southeast Asian anticoagulant market is expected to reach USD 550.7 million by 2029, growing at 7.84% CAGR, while Indonesia’s market alone is projected to expand at 7.72% CAGR, reaching USD 140.3 million by 2029.
“India’s pharmaceutical exports to Indonesia were valued at USD 84.53 million in 2023, reflecting strong trade ties between the two nations,” said Mrs. Aditi Chaudhary, President, International Business, Venus Remedies. “While anticoagulants remain a key focus, we are also expanding into other therapeutic areas to address critical medical needs and improve patient outcomes with affordable generic drugs.”
With over a dozen global marketing authorisations for Enoxaparin, Venus Remedies continues to strengthen its presence in international markets, reinforcing its commitment to advancing accessible healthcare solutions.
About Venus Remedies
Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP. Apart from GMP accreditations, other approvals related to Quality Management (ISO 9001:2015), Environment Management (ISO 14001: 2015), Occupational Health & Safety Management (ISO 45001:2018) are maintained. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 138 patents worldwide and having more than 75 registered trademarks and more than 15 copyrights for its innovative research products. Moreover, in 2025, Venus Remedies received recognition as a ‘Great Place to Work’ for the fourth consecutive time.
Reach out to us at PR Desk
Read more on our Partner sites: Dais World | The Progress Catalyst
Get rewarded for your reading habits on the Dais World app!
